Xtrem Biotech
-
DATABASE (56)
-
ARTICLES (44)
Founded in 1993, WI Harper Group is a venture capital firm investing in early to growth stage companies across the US, Greater China and Asia Pacific. The group has invested in more than 400 companies in the fields of healthcare, biotech, artificial intelligence, robotics, fintech, sustainability and new media. It manages seven venture capital funds with over 100 successful IPO and M&A exits. With three strategic offices in San Francisco, Beijing and Taipei, the group seeks investment opportunities both in the US and Asia.
Founded in 1993, WI Harper Group is a venture capital firm investing in early to growth stage companies across the US, Greater China and Asia Pacific. The group has invested in more than 400 companies in the fields of healthcare, biotech, artificial intelligence, robotics, fintech, sustainability and new media. It manages seven venture capital funds with over 100 successful IPO and M&A exits. With three strategic offices in San Francisco, Beijing and Taipei, the group seeks investment opportunities both in the US and Asia.
Founded in Hong Kong in 2018, Lake Bleu Capital currently operates in both Hong Kong and Shanghai. With assets worth billions of US dollars under management, it mainly invests in pharmaceuticals, biotech, medical devices and healthcare services companies in Asia, especially Greater China. Its limited partners include sovereign wealth funds, university endowments, foundations, pension funds, and family offices across the world.With a long-term investment strategy, Lake Bleu Capital invests through both public and private equity with a focus on mid- to late-stage companies.
Founded in Hong Kong in 2018, Lake Bleu Capital currently operates in both Hong Kong and Shanghai. With assets worth billions of US dollars under management, it mainly invests in pharmaceuticals, biotech, medical devices and healthcare services companies in Asia, especially Greater China. Its limited partners include sovereign wealth funds, university endowments, foundations, pension funds, and family offices across the world.With a long-term investment strategy, Lake Bleu Capital invests through both public and private equity with a focus on mid- to late-stage companies.
Silicon Valley Future Capital is a venture capital firm that invests primarily in early stage and growth stage companies with disruptive technologies or innovative business models. Founding partner Dr. Hong Miao used to be managing partner of CLI Ventures, senior VP of CheerLand Investment Group, executive president of the CL Institute of Innovation, and chairman of Zen Water Capital in Silicon Valley. The firm invests primarily in innovations in high-tech, including artificial intelligence, machine learning, big data, cloud computing, robotics, life science, biotech, precision medicine and other disruptive technologies.
Silicon Valley Future Capital is a venture capital firm that invests primarily in early stage and growth stage companies with disruptive technologies or innovative business models. Founding partner Dr. Hong Miao used to be managing partner of CLI Ventures, senior VP of CheerLand Investment Group, executive president of the CL Institute of Innovation, and chairman of Zen Water Capital in Silicon Valley. The firm invests primarily in innovations in high-tech, including artificial intelligence, machine learning, big data, cloud computing, robotics, life science, biotech, precision medicine and other disruptive technologies.
Security Trading Oy is a Finnish investment company located in Helsinki generating a turnover of $125m in sales. The firm recently invested in the biotech material startup Infinited Fiber, along with Adidas and Invest FWD A/S, which is BESTSELLER’s investment arm for sustainable fashion. Security Trading Oy was part of the Kone Corporation group that was re-organized by the Herlin family, with Antti Herlin as the controlling shareholder in 2005.
Security Trading Oy is a Finnish investment company located in Helsinki generating a turnover of $125m in sales. The firm recently invested in the biotech material startup Infinited Fiber, along with Adidas and Invest FWD A/S, which is BESTSELLER’s investment arm for sustainable fashion. Security Trading Oy was part of the Kone Corporation group that was re-organized by the Herlin family, with Antti Herlin as the controlling shareholder in 2005.
Salut Monràs is Wealth Manager and CEO of Valra Finances, S.L., a family holding company with financial assets and investments in Biotech, AI, Fintech and real estate. She has broad experience in communication, production and design and is passionate about aesthetics and creativity. She is a mother of three and a former international model, professor and entrepreneur. She is general manager of Lorda, S.L., model agent and booker for Francina Modelling Agency and is also founder of Mother Studio and co-founder and commercial director of HELMUTANDCO. She has a degree in Graphic Design from the Ramon Llull University.
Salut Monràs is Wealth Manager and CEO of Valra Finances, S.L., a family holding company with financial assets and investments in Biotech, AI, Fintech and real estate. She has broad experience in communication, production and design and is passionate about aesthetics and creativity. She is a mother of three and a former international model, professor and entrepreneur. She is general manager of Lorda, S.L., model agent and booker for Francina Modelling Agency and is also founder of Mother Studio and co-founder and commercial director of HELMUTANDCO. She has a degree in Graphic Design from the Ramon Llull University.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Rick Klausner is an award-winning scientist, former executive director of the Bill & Melinda Gates Foundation and an entrepreneur. Cell and molecular biologist Klausner was also director of the US National Cancer Institute from 1999-2001 and currently serves as CEO at biotech Lyell Immunopharma working with cell-based technology. He has also co-founded three US healthcare startups to date, Juno Therapeutics in 2013, MindStrong Health in 2014 and GRAIL in 2015. In 2021, he participated as an investor in the $48m Series A round of Dutch cell-based meat startup Meatable which leverages pluripotent stem cells for the first time in foodtech.
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Alta Life Sciences (Alta LS) was established in 2016. Based in Barcelona, the management team is led by the co-founder of Alta Partners Guy Paul Nohra, a leading pioneer VC in life sciences. Alta Partners has funded over 150 companies since 1996. Alta LS specializes in the life sciences sector in Spain and abroad, targeting biotech, genomics, medical devices, diagnostics and digital health. It also acts as a bridge fund, connecting the Spanish life sciences ecosystem to VC experts in Silicon Valley. Investment is available for all stages of development, with focus mainly on seed and Series A funding.
Alta Life Sciences (Alta LS) was established in 2016. Based in Barcelona, the management team is led by the co-founder of Alta Partners Guy Paul Nohra, a leading pioneer VC in life sciences. Alta Partners has funded over 150 companies since 1996. Alta LS specializes in the life sciences sector in Spain and abroad, targeting biotech, genomics, medical devices, diagnostics and digital health. It also acts as a bridge fund, connecting the Spanish life sciences ecosystem to VC experts in Silicon Valley. Investment is available for all stages of development, with focus mainly on seed and Series A funding.
Formerly known as Guangdong Technology Venture Capital Group, Technology Financial Group is a state-owned firm based in Guangzhou. It has a subsidiary in Guangdong province and has set up nine offices in other provinces across China. Technology Financial Group began investing in companies when it was founded in 1992, and it has assets under management of RMB 50bn. With a focus on VC investment, it also provides financial services such as asset management.The firm invests mainly in the high-end equipment manufacturing; new-generation information technology; new material; art, entertainment and media; consumption; biotech and pharmacy; energy and environmental protection; and automotive sectors.
Formerly known as Guangdong Technology Venture Capital Group, Technology Financial Group is a state-owned firm based in Guangzhou. It has a subsidiary in Guangdong province and has set up nine offices in other provinces across China. Technology Financial Group began investing in companies when it was founded in 1992, and it has assets under management of RMB 50bn. With a focus on VC investment, it also provides financial services such as asset management.The firm invests mainly in the high-end equipment manufacturing; new-generation information technology; new material; art, entertainment and media; consumption; biotech and pharmacy; energy and environmental protection; and automotive sectors.
Established in 2018, Jensen Group Investment Fund is the generalist investment fund of Danish entrepreneur Steen Ulf Jensen, founder of the Jensen Group, a global manufacturer of machines for the heavy-duty laundry industry based in Belgium. Jensen was also the CEO of Box TV and Digicel Cabel. The fund has so far invested in four startups with Jensen becoming board chairman at the investee companies. In 2020, the fund acquired stakes in the July €1.1m seed round of Danish alt-leather biotech Beyond Leather Materials and in the funding of Danish bike lock startup PentaLock earlier in March.
Established in 2018, Jensen Group Investment Fund is the generalist investment fund of Danish entrepreneur Steen Ulf Jensen, founder of the Jensen Group, a global manufacturer of machines for the heavy-duty laundry industry based in Belgium. Jensen was also the CEO of Box TV and Digicel Cabel. The fund has so far invested in four startups with Jensen becoming board chairman at the investee companies. In 2020, the fund acquired stakes in the July €1.1m seed round of Danish alt-leather biotech Beyond Leather Materials and in the funding of Danish bike lock startup PentaLock earlier in March.
Co-founder of Meatable
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Mark Kotter is the Austrian co-founder at Dutch cell-based meat startup Meatable, the first to use pluripotent stem cells and claim a highly scalable culture technology, which was developed by Kotter prior to founding the startup in 2018. He is also founder at his biotech startup, bit.bio, which is based in Cambridge, UK, since 2016, where he applies his cellular technological innovation to human stem cell research and has raised investments totaling $42m. His main full-time position is at the University of Cambridge, where he has worked since 2009. He has spent more than five years as a clinician-scientist in stem cell research and was previously a lecturer in neurosurgery. Kotter also lectures at Paris Descartes University and is a team leader at the UK’s National Institute for Health Research’s Brain Injury MedTech Co-operative. He also founded Myelopathy.org to raise awareness of cervical myelopathy. His past positions were as a research group leader at the Max Planck Institute for Experimental Medicine for one year, and for two years spent at the Medical University of Vienna. Kotter holds two doctorates; one in philosophy from the University of Cambridge and the other in medicine from the University of Graz in Austria. Kotter also holds a master’s in philosophy from the University of Cambridge.
Founded in 1997, Seventure Partners is one of Europe’s most prolific VC investors with a portfolio of over 200 startups across both tech and non-tech sectors. The French VC has also managed more than 40 exits in total. It mainly focuses on fintech and insurtech, French and German startups and in life sciences in Europe, North America and Asia.Its five funds cover different market segments, ranging from €24m–€200m, with investments of €500,000–€10m per round. Total funding for a company can reach €20m, right through the early to late stages. Recent investments include the $6.7m Series A round of US biotech Dermala and the $10.7m Series A round of US self-cleaning water bottle startup LARQ.
Founded in 1997, Seventure Partners is one of Europe’s most prolific VC investors with a portfolio of over 200 startups across both tech and non-tech sectors. The French VC has also managed more than 40 exits in total. It mainly focuses on fintech and insurtech, French and German startups and in life sciences in Europe, North America and Asia.Its five funds cover different market segments, ranging from €24m–€200m, with investments of €500,000–€10m per round. Total funding for a company can reach €20m, right through the early to late stages. Recent investments include the $6.7m Series A round of US biotech Dermala and the $10.7m Series A round of US self-cleaning water bottle startup LARQ.
Vesalius Biocapital III is a €70 million fund that invests in medtech, e-health initiatives and drug development in Europe. It was launched in 2017 by Luxembourg-based Vesalius Biocapital, a life sciences venture capital firm founded in 2007. Preceding Vesalius Biocapital III were Vesalius Biocapital I, with €76 million under management and Vesalius Biocapital II, which has €78 million invested; both funds have 11 portfolio companies each.Its recent investments include in Portuguese home physiotherapy tech solution SWORD Health's 2021 $25m Series B and in the 2020 $9m second phase of its Series A round as well as in the 2020 €22m Series B round of German biotech Topas Therapeutics.
Vesalius Biocapital III is a €70 million fund that invests in medtech, e-health initiatives and drug development in Europe. It was launched in 2017 by Luxembourg-based Vesalius Biocapital, a life sciences venture capital firm founded in 2007. Preceding Vesalius Biocapital III were Vesalius Biocapital I, with €76 million under management and Vesalius Biocapital II, which has €78 million invested; both funds have 11 portfolio companies each.Its recent investments include in Portuguese home physiotherapy tech solution SWORD Health's 2021 $25m Series B and in the 2020 $9m second phase of its Series A round as well as in the 2020 €22m Series B round of German biotech Topas Therapeutics.
Founded in 2012, Purple Orange’s objective is to support the transition away from animals in the food chain, supporting early-stage food and biotech companies across the globe with a focus on alternative proteins and cellular agriculture. It currently has 12 startups from different nations in its portfolio. Its most recently disclosed investments have been in the December 2020 pre-seed round of Chinese cultured meat startup CellX and in the November 2020 $500,000 pre-seed round of Swedish plant-based food vending startup VEAT.
Founded in 2012, Purple Orange’s objective is to support the transition away from animals in the food chain, supporting early-stage food and biotech companies across the globe with a focus on alternative proteins and cellular agriculture. It currently has 12 startups from different nations in its portfolio. Its most recently disclosed investments have been in the December 2020 pre-seed round of Chinese cultured meat startup CellX and in the November 2020 $500,000 pre-seed round of Swedish plant-based food vending startup VEAT.
Rubio Impact Ventures (formerly Social Impact Ventures)
Founded in Amsterdam in 2014, Rubio Impact Ventures was formerly known as Social Impact Ventures. The VC currently invests in sustainability-focused startups that are predominantly based in the Netherlands and north-western Europe. It currently has 27 portfolio companies including fair coffee brand Wakuli and cultured meat pioneer Masa Meat. The “Rubicon crossing” VC has just raised €110m for its second impact fund, Rubio Fund 2, in October 2021.Recent investments include participation in the $43m Series B round of food-sharing app OLIO in September 2021 and the €3.6m seed round in July 2021 for Portuguese Arborea that uses micro-organisms in biotech for foodtech applications.
Founded in Amsterdam in 2014, Rubio Impact Ventures was formerly known as Social Impact Ventures. The VC currently invests in sustainability-focused startups that are predominantly based in the Netherlands and north-western Europe. It currently has 27 portfolio companies including fair coffee brand Wakuli and cultured meat pioneer Masa Meat. The “Rubicon crossing” VC has just raised €110m for its second impact fund, Rubio Fund 2, in October 2021.Recent investments include participation in the $43m Series B round of food-sharing app OLIO in September 2021 and the €3.6m seed round in July 2021 for Portuguese Arborea that uses micro-organisms in biotech for foodtech applications.
Xtrem Biotech, an agritech startup from Granada, seeks global expansion
With its research roots in the University of Granada, Xtrem Biotech was named one of the world's most innovative agtech spin-offs by accelerator TERRA Food & AgTech
Daniel Oliver: Building a "Facebook" for investments in biotech startups
The biologist and crowdfunding expert has pioneered the growth of Spanish biotech startups, providing access to early-stage investments, with support from scientific experts worldwide
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Forget solar panels and batteries, Bioo wants to scale soil bioelectricity generation
Improving on NASA’s microbial fuel cell tech, Bioo hopes to boost crop efficiency and transform the way urbanites live, in future green cities powered by plants
TurtleTree Labs: Creating sustainable mammalian milk alternatives from stem cells
Founder’s search for high-quality dairy milk led to the creation in a lab of naturally occurring ingredients found in human milk for supply to dairy milk and infant formula businesses
Sequoia Capital China holds steady with investments in healthcare, biotech and green economy
China’s most active investor increases bets on sectors beyond the consumer internet and edtech recently hurt by regulatory clampdown
Because Animals: Pioneering cultured meat for pets
The biotech startup is disrupting the pet food processing industry with cell-based food to minimize environmental “pawprints” and promote animal welfare
NovoNutrients: Tackling the dual problems of CO2 emissions and over-fishing
The first to transform CO2 to fish food, NovoNutrients is trialing with industry giants Skretting and Chevron, and will soon raise Series A funding
Poliloop: Tackling pollution crisis with plastic-eating bacteria for industrial use
Hungarian biotech Poliloop is closing $2m seed funding for “bacteria cocktail” that breaks down plastic into organic waste quickly, enabling more affordable and eco-friendly waste management
Qorium: Lab-grown premium leather for the future of luxury
The Dutch biotech startup co-founded by cell-based meat pioneer Mark Post is targeting the luxury goods market with its “clean leather” sheets made from cultivating bovine skin cells, and plans to raise up to €100m
Mycorena: Fungi-based vegan protein challenging traditional plant-based ingredients
Award-winning Swedish biotech startup is scaling production of mycoprotein to become a key player in the emerging market for functional proteins
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
New Food Invest: Opportunities in the European alt-protein space
With a record €2.4bn investment in 2019, Europe’s foodtech sector appears poised for continued growth, but startups, corporations, governments and even universities can do more, experts say
Future Food Asia by ID Capital: Introducing Asia's agrifood startups to the world
More than a meeting of startups and investors, the conference showcases ID Capital’s investment thesis and Big Ag’s support for agrifood tech in the world’s most populous region
Cubiq Foods: Bioreactor farms producing the food of tomorrow
Growing appetite for meat alternatives expected to fuel demand for Cubiq’s low calorie, Omega 3-enriched lab-grown fats
Sorry, we couldn’t find any matches for“Xtrem Biotech”.
